Infinimmune Raises $75 Million for Two Atopic-Dermatitis Antibodies

Company: Infinimmune · Event Type: Deal and Financing · Product/Asset: IFX-101 · Subject: Atopic Dermatitis · Event Date: August 11, 2026 Summary Infinimmune closed a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance two wholly owned, half-life-extended antibodies for atopic…